Sarepta says no to right to try for its DMD therapies

Following data from a small trial of a Duchenne muscular dystrophy gene therapy, Sarepta Therapeutics Inc. (NASDAQ:SRPT) told BioCentury that it will not offer pre-approval access under right-to-try legislation or FDA’s expanded access program for any of its DMD candidates. The company said such programs can pose a challenge to drug approval.

"Our goal is to get the drug to the most patients as efficiently as possible," said Sarepta spokesperson Ian Estepan. "It becomes challenging to do that with compassionate use programs or right to try."...